Close Menu

cell-free DNA

The company has been working with NGS-based ctDNA testing for some time in research, but has now made its first move into the clinical sphere.

The company has been working with pharmaceutical companies to support clinical trials and drug development with its unique combined DNA and RNA liquid biopsy platform.

Results from a study have spurred a new prospective trial comparing arrays, sequencing, and several single-marker assays in men receiving hormonal therapies.

A University of Toronto team developed the probes to improve upon its previously described electrochemical clamp assay technology.

Teneovita will distribute Biocept's test services to hospitals, oncology centers, and individual medical practices throughout the country.

A study by researchers in Austria suggests read depth patterns upstream of transcription start sites can provide clues to gene expression.

Last month, the foundation, in partnership with the Washington State Department of Health, released seven educational videos about prenatal testing.

A Winthrop-University Hospital team showed that demethylated circulating cell-free DNA from dying oligodendrocytes is a biomarker for relapsing-remitting MS.

The researchers said that this property of ctDNA could be exploited to improve the sensitivity of liquid biopsies.

In a pilot study, investigators identified infection-causing agents by sequencing microbial DNA in patient blood samples.

Pages

Nobel laureates and scientific societies urge NIH and the Department of Health and Human Services to revisit the recent decision to end funding for a coronavirus grant.

Bloomberg reports that BGI's SARS-CoV-2 testing sites in the Middle East have raised concerns among US officials.

A new Pew Research Center poll finds confidence in medical researchers has grown among US adults since the start of the coronavirus pandemic.

In Science this week: machine learning algorithm for faster Mendelian disorder diagnoses, gene linked to safe response to nitrogen-containing bisphosphonates, and more.